Five Years of Ublituximab in Multiple Sclerosis

What is the long-term clinical efficacy and safety of ublituximab in people with relapsing multiple sclerosis (RMS)?In this trial including 985 adults, participants treated with continuous ublituximab for up to 5 years in the open-label extension study after completion of the randomized Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (ULTIMATE) had significantly lower annualized relapse rate and confirmed disability progression than those initially treated with teriflunomide. The overall safety profile of ublituximab remained consistent with no new safety signals emerging with prolonged treatment.Results suggest that early initiation of ublituximab and continued treatment over a period of 5 years provided sustained clinical benefits in participants with RMS.

Corresponding Author: Bruce A. C. Cree, MD, PhD, MAS, 675 Nelson Rising Lane, #221C, San Francisco, CA 94158 (bruce.cree@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.